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Abstract
Background: This study characterizes the historical relationship between coverage of measles containing vaccines (MCV)
and mortality in children under 5 years, with a view toward ongoing global efforts to reduce child mortality.
Methodology/Principal Findings: Using country-level, longitudinal panel data, from 44 countries over the period 1960–
2005, we analyzed the relationship between MCV coverage and measles mortality with (1) logistic regressions for no
measles deaths in a country-year, and (2) linear regressions for the logarithm of the measles death rate. All regressions
allowed a flexible, non-linear relationship between coverage and mortality. Covariates included birth rate, death rates from
other causes, percent living in urban areas, population density, per-capita GDP, use of the two-dose MCV, year, and
mortality coding system. Regressions used lagged covariates, country fixed effects, and robust standard errors clustered by
country. The likelihood of no measles deaths increased nonlinearly with higher MCV coverage (ORs: 13.8 [1.6–122.7] for 80–
89% to 40.7 [3.2–517.6] for $95%), compared to pre-vaccination risk levels. Measles death rates declined nonlinearly with
higher MCV coverage, with benefits accruing more slowly above 90% coverage. Compared to no coverage, predicted
average reductions in death rates were 279% at 70% coverage, 293% at 90%, and 295% at 95%.
Conclusions/Significance: 40 years of experience with MCV vaccination suggests that extremely high levels of vaccination
coverage are needed to produce sharp reductions in measles deaths. Achieving sustainable benefits likely requires a
combination of extended vaccine programs and supplementary vaccine efforts.
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Introduction
Historically, measles infections have been a major cause of
morbidity and mortality in children, even though effective measles
containing vaccines (MCV) were first developed more than 40
years ago [1]. Global efforts to prevent measles deaths have
aligned around the United Nations’ Millennium Development
Goals (MDG), which identify childhood mortality reduction as a
key priority, specifically calling for a two-thirds reduction in
mortality among children under age 5, between 1990 and 2015
(MDG 4). MCV vaccination programs form a cornerstone of these
efforts with ambitious targets, including universal childhood
measles vaccination and 90% reductions in measles deaths from
year 2000 levels (733,000 worldwide) [2].
Thus far, substantial progress has been made. In 2008, there
were an estimated 164,000 measles deaths, a 78% reduction
compared to mortality in 2000 [2]. However, the continued
effectiveness of vaccination efforts depends on the interaction of
numerous socio-demographic and systemic factors that define
patterns of measles transmission, effectiveness of vaccination
programs, and survival of infected children. In light of these
challenges, it is important to monitor program scale-up and gauge
whether advances in vaccination coverage will be sufficient to
attain global targets for reducing measles mortality [3,4,5,6].
As efforts proceed to expand coverage and sustain the benefits
of vaccination in countries with the highest burdens of measles
mortality, our aim in this study was to quantify the relationship
between historical MCV coverage increases and reductions in
child mortality in light of related demographic and economic
factors, and critically consider the implications of our findings for
current vaccination efforts in high-burden settings.
Methods
We used regression analyses to assess the relationship between
MCV coverage and measles mortality in children under five years,
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models related changes in measles mortality in children under 5
years of age to changes in MCV coverage levels over time within
each country while adjusting for country-level variables. Vaccina-
tion coverage is expected to influence measles incidence, which in
turn will impact on measles mortality, through the mediating effect
of the case fatality rate (CFR). Because epidemiological targets are
expressed in terms of mortality reductions, and because accurate
measles incidence data are difficult to obtain for many countries,
we chose to model a reduced-form relationship between MCV
coverage and mortality. By examining the coverage-mortality
relationship within countries and over time and by including
country-level variables that are likely to influence incidence, CFR,
or both, our aim was to minimize potential confounding in
characterizing the relationship between MCV and mortality.
Model variables
The primary outcome of interest was the measles-specific death
rate for children under five years, computed as the number of
deaths classified as measles divided by the at-risk population (i.e.
children under 5) in a given country and year. The main
independent variable was the proportion of 1–2 year-olds
vaccinated with at least one dose of MCV during the year. We
hypothesized that: (a) higher MCV coverage is strongly related to
lower measles mortality, although the relationship will be non-
linear, consistent with herd immunity [7]; (b) the likelihood of
having no measles deaths in a country-year increases as MCV
coverage increases, consistent with stochastic fade-out and local
eradication [8].
Other covariates were included in the models because of their
direct or indirect relationships with measles mortality or their
potential to modify the relationship between MCV coverage and
measles mortality. We included an indicator of whether a country-
year’s vaccination schedule recommended two MCV doses. Two-
dose vaccination was introduced to increase immunity to measles
infection [9,10]. Therefore, a given level of MCV coverage with a
two-dose course could lead to greater reductions in measles
mortality than with a single dose.
We included changes in determinants of infectious disease
epidemic dynamics: population density, proportion living in urban
areas, and crude birth rate in a given country and year. Higher
population density increases contact rates and transmission.
Greater urbanization increases contact rates for urban dwellers,
but also reduces travel distances to medical facilities. Its net effect
on measles mortality is unclear. Higher birth rates increase the
influx of susceptible individuals leading to greater epidemic risk.
The models included changes in socioeconomic determinants of
health over time: real per-capita gross domestic product (GDP)
(2000 international dollars) and mortality rates from all causes
other than measles in children under five years. Increasing GDP is
associated with reduced sickness and improved survival, likely
related to improvements in education, nutrition, public health, and
health care [11,12,13,14].
Year and mortality coding system (International Classification
of Disease (ICD) version) were included to enhance outcome
comparability over time. Observation year reflects secular trends
not captured by other variables. Changes in ICD coding system
can cause otherwise similar deaths to be classified differently,
artificially changing apparent measles mortality.
Data sources and inclusion criteria
The WHO Mortality Database provided age-specific death
rates by cause, and with a specified coding system, collected in a
common format [15]. A previous study [16] provided quality
ratings for each country’s mortality data. Vaccine coverage after
1980 was derived from WHO/UNICEF estimates [17]. WHO/
UNICEF estimates were used instead of Demographic and Health
Surveys (DHS) since, although DHS vaccination data are often
used in analyses of vaccination [18,19], they are not available for
most countries that we were able to evaluate in this analysis. For
vaccine coverage prior to 1980, we relied on country-specific
reports (Section S1 in Appendix S1). WHO provided data on the
year in which a country introduced a two-dose MCV schedule
[20]. Other data were derived from the World Bank [21], United
Nations Population Division [22], and the Penn World Tables
[23]. For 1960–2005, countries were only included in the analysis
if they had country-years with medium or high-quality mortality
data, and MCV coverage as well as all other covariates were
available (Section S1 in Appendix S1).
Statistical methods
Data analysis was undertaken using longitudinal panel regres-
sions. Logistic regression was used to assess the odds of having no
measles deaths in under-5 children in a given country-year
compared to pre-vaccination risk levels. Linear regression was
used to model the log death rate from measles in a given country-
year (Section S2 in Appendix S1). In all models, aside from
observation year, all independent variables that are not indicators
or percentages were log-transformed so estimated coefficients
could be interpreted as elasticities [24]. For example, the model
coefficient for MCV coverage may be understood as the percent
change in measles mortality rates for children under 5 associated
with a 1% change in coverage. Independent variables other than
observation year and ICD coding system were lagged by 1 year.
Country-level fixed effects were included to absorb unobserved
country-level heterogeneity (e.g., determinants of variation in case
fatality rates not explained by other covariates in the model), and
robust standard errors, clustered by country, were estimated using
the jackknife method.
Since the relationship between coverage and mortality is not
necessarily linear, coverage was either categorized using indicator
variables or entered as restricted cubic splines [25]. We divided MCV
coverage into six categories: 0%; 1–59%; 60–79%; 80–89%; 90–
94%; and $95% coverage. These divisions were prospectively
defined so the numbers of observations in each level above 0% were
nearly equal and cutoffs were divisible by 5. The restricted cubic
splinespecificationusedthesamecutoffs(SectionS2inAppendixS1).
To translate the spline regression results into interpretable
mortality/coverage relationships for different starting MCV coverage
levels, we estimated the expected percent reduction in under-5
measles-specific mortality and associated confidence intervals with
simulations. The simulations comprised 20,000 random draws of all
model coefficients from multivariate normal distributions using the
estimated regression coefficients and their associated variance-
covariance matrix. With each set of coefficients, we calculated
expected measles-specific mortality rates at MCV coverage levels
from 1% to 99%. Then, to reflect the change in measles mortality
related to increases in coverage, we calculated reduction in measles-
specific mortality associated with increasing MCV coverage to 90–
99% from coverage levels of 50–95%. We similarly calculated
interquartile ranges and 5th and 95th percentiles.
We examined the sensitivity of our results to key assumptions.
The restricted cubic spline model specification was compared to:
1) a model without MCV coverage; and 2) a model with a constant
log-linear relationship between MCV coverage and mortality.
Alternative specifications were compared using Akaike and
Bayesian Information Criteria [26,27]. We also used these
Information Criteria to assess alternative categorizations of
Vaccination and Measles Deaths
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coverage by one year compared to a model in which MCV
coverage was averaged over the previous 5 years. We assessed the
impact of non-linear time trends by comparing the main model
with one using year fixed effects. We explored other statistical
models including negative binomial regressions. To consider the
potential relevance of the historical patterns to countries with large
measles burden at present, we assessed potential bias by
reanalyzing subsets of countries from our full dataset with lower
and higher per-capita GDP.
All analyses were undertaken using Stata/SE 10.0 (StataCorp,
College Station TX).
Results
The countries and years included in our analysis spanned broad
ranges in terms of measles mortality, birth rate, urban population
and density, and MCV coverage (Table 1). Countries were mostly
middle- to high-income, as the analysis required higher-quality
vital registration systems. Nonetheless, all MCV coverage levels
were represented, with MCV coverage above 60% in the majority
of years.
Higher MCV coverage was associated with a greater chance of
having no measles deaths in children under 5 in a given year
(Table 2). Coverage levels $80% were significantly and positively
associated with no measles deaths in the multivariable model.
Without MCV vaccination, the model predicted that 5% of
country-years would be free of measles deaths for children under 5
years, increasing to 69% of country-years when MCV coverage
exceeded 95%.
Coverage levels above 60% were associated with increasingly
significant reductions in measles mortality in the multivariable
model. Table 3 shows the relationship between MCV coverage
and measles death rates in children under 5. Measles mortality
declined most rapidly as MCV coverage increased from 30%
through 75% (from 226% to 283% over this range), while at
MCV coverage above 85%, further mortality declines were
significant but smaller in scale (an additional 25% from 85% to
99% coverage).
Both observation year and crude birth rate also were
significantly associated with measles death rates (Table 3). There
was an expected 12% decline in measles deaths each year, holding
all other model variables fixed. Higher birth rates were associated
with higher measles mortality rates, with a 1% increase in birth
rate associated with a 3.5% increase in measles death rate. This is
consistent with the observation that faster entry of susceptible
individuals into the population makes measles outbreaks more
likely.
Notably, though not reaching statistical significance at the
p,0.05 level, results were suggestive that the introduction of a
2-dose measles vaccination course were related to a greater chance
of having no measles deaths in a given year and to lower measles
mortality levels in children under 5 years of age (Table 2 and
Table 3).
While substantial gains are expected with increased MCV
coverage, the expected magnitude of additional gains are less
certain at coverage levels above 90%. Figure 1 shows the expected
impact of increasing MCV coverage from various starting levels to
90% (Panel A), 95% (Panel B), or 99% (Panel C). For example,
increasing from 75% to 90% MCV coverage reduces measles
mortality rates by 60% (interquartile range: 53–69%; 5th to 95th
percentile: 36–77%).
The main findings were assessed in sensitivity analyses (Sections
S3, S4, S5, and S6 in Appendix S1). The findings were robust to a
range of alternative methodological choices and assumptions, with
estimated benefits in the sensitivity analyses differing by less than
15% from those reported in the main analysis. Importantly,
because current measles burdens are in countries that are
generally poorer than those in our data set, we assessed the
associations between MCV and measles mortality for countries
stratified by per-capita GDP (above/below $7,000) for countries in
our data set. We found that poorer countries had greater benefit
from increased MCV coverage, though benefits differed by no
more than 5%.
Discussion
Forty years of international experience with the impact of
measles vaccination programs on child mortality suggests that
sustained high levels of MCV coverage, along with other factors,
contributed to dramatic declines in measles deaths. In light of
current efforts to improve child health, measles vaccination has
played and will continue to play an important role. As the Measles
Initiative reports, impressive reductions have been achieved in
some countries with previously high measles mortality rates [28],
though there is still much work to be done.
This analysis has several strengths. It characterizes the historical
relationship between MCV coverage and mortality as observed
Table 1. Characteristics of the study sample.*
Values
(n=980)
ICD-7 coding system used, % of country-years 18.4
ICD-8 coding system used, % of country-years 19.7
ICD-9 coding system used, % of country-years 55.4
ICD-10 coding system used, % of country-years 6.5
High quality mortality data, % of country-years) 31.7
Measles death rate, per 100,000 children under
5 per year, mean (SD)
7.0 (29.3)
No measles deaths observed, % of country-years 38.7
Background mortality rate, per 100,000 children
per year, mean (SD)
1,291.1 (1,289.3)
MCV coverage, % of 12–24 month-olds, mean (SD) 57.4 (39.6)
MCV coverage of 1–59%, % of country-years 12.6
MCV coverage of 60–79%, % of country-years 14.7
MCV coverage of 80–89%, % of country-years 14.2
MCV coverage of 90–94%, % of country-years 14.7
MCV coverage of $95%, % of country-years 17.3
Two doses of MCV, % of country-years 30.4
Crude birth rate, per 1,000 adults per year, mean (SD) 19.0 (9.1)
Population density, per sq km, mean (SD) 102.3 (100.5)
Under-5 population, millions, mean (SD) 2.8 (4.5)
Urban, % of population, mean (SD) 67.4 (14.5)
Per-capita GDP, in 2000 international dollars, mean (SD) 12,853 (7,629)
*Countries included in the analysis: Austria, Azerbaijan, Belarus, Belgium, Belize,
Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Cuba, Denmark, El
Salvador, Finland, France, Germany, Guatemala, Hungary, Ireland, Israel, Italy,
Kazakhstan, Kuwait, Kyrgyzstan, Luxembourg, Mexico, Netherlands, Norway,
Panama, Republic of Korea, Romania, Russian Federation, Spain, Sweden,
Switzerland, TFYR Macedonia, Turkmenistan, Ukraine, United Kingdom, United
States of America, Uruguay, Uzbekistan, and Venezuela.
doi:10.1371/journal.pone.0013842.t001
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relationship, conditioning on country differences likely to impact
the population dynamics of measles. It captures nonlinearities in
the relationship between coverage and mortality, relevant for
considering potential health benefits due to increased coverage for
countries starting at different MCV coverage levels.
The analysis also has limitations. Data were drawn from
multiple sources and rely in part on country –reports on mortality
and vaccination coverage. While we cannot rule out bias, the fact
that the estimated effects of covariates such as crude birth rate
were consistent with their expected directions offers some
reassurance. Additionally, we estimated coverage-mortality rela-
tionships for countries with higher quality vital registration,
adjusted for changes in ICD coding and year, and included
country fixed effects. Further, we identified effects of vaccination
from distinct patterns of within-country longitudinal variation in
vaccination rates, adjusting for a wide array of variables that likely
capture important variation across countries. We also found that
our results were robust to various methodological choices in a
broad array of sensitivity analyses.
The analysis used national estimates of measles deaths and
measles coverage, and therefore cannot comment on the effects of
sub-national heterogeneity. These effects likely blunt the impact of
vaccine coverage on measles reductions, particularly in larger
countries. Our use of country fixed-effects and the explicit
inclusion of other potential determinants of unequal MCV
coverage within countries aimed to mitigate this to a certain
extent.
Because of limitations in data availability, our analysis could not
include countries from Africa or the Indian subcontinent.
Differences between these countries and those in our dataset (for
example, high rates of under-nutrition in the former) limit our
ability to make precise out-of-sample projections. Additionally,
case fatality rates (CFR) may also be higher in lower-income
countries not included in our data set [29]. We used country
fixed effects and controlled for observation year to account for
difference that remained constant across countries or that changed
similarly across countries over time. We also conducted sensitivity
analyses to assess differences in findings by per-capita GDP level or
region. None of these analyses showed evidence of strong bias
(Section S1 in Appendix S1), but we suggest caution in
extrapolating to specific countries outside of our dataset.
Notwithstanding these limitations, the historical patterns
examined in this study do offer important insights relevant to
present circumstances. Specifically, they suggest that very high
coverage levels, perhaps well above 95%, sustained over
substantial periods of time, are likely needed to achieve the types
of reductions observed historically. Furthermore, our main results
suggest that the use of second doses of MCV — as an example of a
vaccination strategy that can complement higher coverage levels
— could be important, especially in countries where higher levels
of malnutrition, greater incidence of diarrhea, and resulting
weaker immunologic responses to vaccines among children are
more common.
While our goals in this study were to use historical data to
estimate a relationship between MCV coverage and measles
mortality, comparison to theoretical models is also appropriate.
Table 2. Results from logistic regression model for having no
measles deaths in children under 5 years.*
Independent variables Odds ratio
95% confidence
interval P-value
MCV coverage of 1–59% 2.743 [0.32–23.27] 0.345
MCV coverage of 60–79% 6.009 [0.66–54.38] 0.108
MCV coverage of 80–89% 13.831 [1.56–122.67] 0.020
MCV coverage of 90–94% 18.863 [2.05–173.32] 0.011
MCV coverage of $95% 40.665 [3.19–517.59] 0.005
ICD-8 coding system 0.390 [0.05–3.13] 0.365
ICD-9 coding system 0.330 [0.02–6.76] 0.461
ICD-10 coding system 0.108 [0.00–3.90] 0.216
Year 1.099 [0.96–1.26] 0.164
Two doses of MCV 1.272 [0.52–3.10] 0.588
Crude birth rate 0.045 [0.00–13.31] 0.276
Urban 0.911 [0.74–1.13] 0.381
Population density 13.768 [0.00–439,572.00] 0.611
Per-capita GDP 5.361 [0.18–160.86] 0.324
Background mortality rate 0.670 [0.32–1.40] 0.279
*Observations: 878; Countries: 38; Observations per country (min: 5; avg: 23.1;
max: 43); F: 9.2; p: ,0.0001.
6 countries accounting for 102 observations could not be included in the
logistic regression because all years had no measles deaths (Belarus and
Luxembourg) or all years had measles deaths (Guatemala, Romania,
Turkmenistan, and Venezuela).
All variables are use indicators except year which is expressed as calendar year,
urban which is expressed percentage, and crude birth rate, population density,
per-capita GDP, and background mortality rate which are all log-transformed
continuous variables.
The comparator for the odds ratios are country-years with 0% MCV coverage
using ICD-7 coding systems without a two-dose MCV course.
doi:10.1371/journal.pone.0013842.t002
Table 3. Results from linear regression model for logged




MCV coverage of 1–59% 20.236 [21.06–0.59] 0.568
MCV coverage of 60–79% 21.639 [22.95– 20.32] 0.016
MCV coverage of 80–89% 22.298 [23.55– 21.05] 0.001
MCV coverage of 90–94% 22.576 [23.85– -1.30] 0.000
MCV coverage of $95% 22.924 [24.18– 21.67] 0.000
ICD-8 coding system 0.499 [20.33–1.33] 0.232
ICD-9 coding system 0.731 [20.95–2.41] 0.386
ICD-10 coding system 1.321 [20.63–3.28] 0.180
Year 20.117 [20.22– 20.01] 0.028
Two doses of MCV 20.396 [21.28–0.48] 0.370
Crude birth rate 3.450 [0.57–6.33] 0.020
Urban 0.078 [20.02–0.17] 0.108
Population density 21.302 [24.03–1.42] 0.340
Per-capita GDP 20.464 [22.29–1.37] 0.611
Background mortality rate 0.300 [21.68–2.28] 0.762
Constant 223.175 [17.16–429.19] 0.034
*Observations: 980; Countries: 44; Observations per country (min: 5; avg: 22.3;
max: 43); R-squared (within: 0.62; between: 0.33; overall: 0.46); F: 129.84; p:
,0.0001.
All variables are use indicators except year which is expressed as calendar year,
urban which is expressed percentage, and crude birth rate, population density,
per-capita GDP, and background mortality rate which are all log-transformed
continuous variables.
The comparator for the odds ratios are country-years with 0% MCV coverage
using ICD-7 coding systems without a two-dose MCV course.
doi:10.1371/journal.pone.0013842.t003
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periodically with years of relatively low measles incidence [30,31].
As vaccination increases, long-run average measles incidence
declines [31]. Through herd immunity – indirect protection of
unvaccinated individuals due to interrupted chains of transmission
– measles may theoretically be eradicated below 100% vaccination
– implying percent reductions greater than MCV coverage levels.
As the proportion of the population vaccinated may be larger than
the proportion achieving immunity because of issues like spoilage,
the opposite may also be true [32]. Measles mortality – a stated
target of the MDGs – is related to vaccination via incidence
multiplied by the case fatality rate. With a constant CFR, mortality
should respond to MCV coverage increases like incidence.
However, CFR depends on a number of factors [29]. For
example, vaccination increases the average age of infection [31]. If
older children are more likely to survive, then mortality may
decline more than incidence.
Results from this analysis are broadly consistent with theoretical
relationships and previous studies. While we do not directly
observe information on interruption in chains of infection
transmission at different coverage levels, we interpret the non-
linearities in the relationship between coverage and mortality as an
indication of herd immunity. A study of measles immunity in
Europe in the pre-vaccine era found that the theoretical
proportion needed to vaccinate at birth to achieve eradication
was between 86% and 97%, suggesting modest herd immunity
effects [33,34]. Similarly, we found that the proportion of country-
years with no observed measles deaths increased sharply at such
coverage levels. Consistent with these findings, we estimated that
the benefits of herd immunity are modest with reduction in
measles deaths a few percentage higher than MCV coverage levels
in the 45–90% coverage range. For MCV coverage below 45%,
reductions in deaths actually lag behind increases in coverage. As
this finding is consistent with the potential failure of vaccination to
provoke sufficient immunity in all children, further emphasis on
vaccination program quality, 2-dose MCV courses, and supple-
mental immunization activities is warranted in countries scaling-
up from low coverage levels.
Sustaining high measles coverage has value in developed and
developing countries. The majority of measles deaths occurs in
resource-poor countries [28]. Simulation studies illustrate the
importance of measles vaccination in these populations [6,35,36],
with estimated benefits similar to our findings. Studies also
highlight the importance of program quality and supplemental
immunization activities. In developed countries, vulnerability to
renewed measles epidemics exists despite longstanding vaccination
programs [37].
Measles vaccination is a cornerstone of preventing childhood
mortality. In over 40 years of worldwide experience with measles
vaccination, impressive reductions in measles incidence and
mortality have been achieved through sustained population
coverage levels above 90%. Given the challenges of sustaining
high measles coverage in countries currently facing large measles
burdens, a combination of extended vaccine programs and
supplementary vaccine efforts should be pursued.
Supporting Information
Appendix S1 Supplemental appendix with supporting informa-
tion.
Found at: doi:10.1371/journal.pone.0013842.s001 (0.35 MB
PDF)
Figure 1. Estimated changes in measles-specific mortality rates for children under 5 years old with increasing MCV coverage. Shown
in the graph is the percentage change in measles-specific mortality rates in children under 5 years associated with increasing MCV coverage to 90%
(Panel A), 95% (Panel B), and 99% (Panel C) from different starting MCV coverage levels (solid colored bars – interquartile ranges; black vertical lines –
5th to 95th percentile ranges).
doi:10.1371/journal.pone.0013842.g001
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